-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

Benzinga·10/07/2026 15:40:05
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.